Understanding intrinsic and acquired resistance to anti-FGFR therapies [ 2014 - ]

Research Grant

Researchers: A/Pr Pamela Pollock (Principal investigator) ,  Dr Nicholas Turner ,  Prof Moosa Mohammadi

Brief description In vitro and in vivo preclinical data suggests that inhibition of FGFR in endometrial cancer patients may be a viable therapeutic approach. Data from other cancers suggests that despite remarkable initial responses to kinase inhibitors, cancer cells eventually develop resistance. This project aims to identify and characterize the mechanisms of resistance that emerge following FGFR inhibition in order to design combination therapies that may delay and/or prevent the emergence of resistance.

Funding Amount $772,012.00

Funding Scheme Project Grants

Notes Standard Project Grant